The nonsteroidal mineralocorticoid receptor antagonist finerenone (Kerendia) unexpectedly showed that it might protect against incident infective pneumonia and COVID-19. The finding was based on ...

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, ...

Please provide your email address to receive an email when new articles are posted on . UACR reductions were noted at 4 months, 1 year and 2 years, according to the researchers. Safety profiles were ...

Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Finerenone reduces CV and renal events in patients with type 2 diabetes and chronic kidney disease, and ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer’s Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to ...

The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (BAY 94-8862, Bayer) improved markers of kidney function when added to a renin-angiotensin system (RAS) blocker in patients with ...

The drug finerenone has a positive effect on patients with type 1 diabetes and chronic kidney disease. The drug reduces the amount of proteins excreted in the urine of these patients. This reduction ...

The appraisal committee considered evidence submitted by Bayer, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...